• SPX
  • $5,995.54
  • 0.38 %
  • $22.44
  • DJI
  • $43,988.99
  • 0.59 %
  • $259.65
  • N225
  • $39,500.37
  • 0.3 %
  • $118.96
  • FTSE
  • $8,072.39
  • -0.84 %
  • -$68.35
  • IXIC
  • $19,286.78
  • 0.09 %
  • $17.32
Biofrontera AG (BFRA) Stock Price, News & Analysis

Biofrontera AG (BFRA) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$2.6
Day's range
$3.1
50-day range
$2.0906
Day's range
$3.75
  • Country: DE
  • ISIN: US09075G1058
52 wk range
$1.5
Day's range
$7.54
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score N/A
  • Piotroski Score N/A
  • Grade Buy
  • Symbol (BFRA)
  • Company Biofrontera AG
  • Price $2.67
  • Changes Percentage (-2.91%)
  • Change -$0.08
  • Day Low $2.60
  • Day High $3.10
  • Year High $7.54

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

  • Last Earnings 02/18/2021
  • Ex-Dividend for 5/16 Dividend 02/24/2021
  • Dividend Payable 03/04/2021
  • Today N/A
  • Next Earnings (Estimated) 04/11/2022
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.61
  • Trailing P/E Ratio -4.3485342019544
  • Forward P/E Ratio -4.3485342019544
  • P/E Growth -4.3485342019544
  • Net Income $-13,023,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.